4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial - a podcast by Vinay Prasad, MD MPH

Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint
No OSBad crossover
Lots to discuss hereI will be covering all the major ASCO papers on @PlenarySession
Subscribe to my substack https://vinayprasadmdmph.substack.com/

Further episodes of Plenary Session

Further podcasts by Vinay Prasad, MD MPH

Website of Vinay Prasad, MD MPH